IDEXX Laboratories (IDXX) Financials: History & Chart

IDEXX Laboratories, Inc. (IDXX)IDXXIDEXX Laboratories, Inc.

About IDEXX Laboratories, Inc.

IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services. In the livestock, poultry, and dairy markets, IDEXX supplies diagnostic and health-monitoring solutions. Its water testing portfolio includes products designed to detect various microbiological contaminants, notably the Colilert, Colilert-18, and Colisure tests for total coliforms and E. coli, as well as Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray products. Beyond these, IDEXX extends its reach to human point-of-care medical diagnostics, offering electrolyte and blood gas analyzers, and SARS-CoV-2 RT-PCR tests. Other key offerings encompass in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers, as well as SNAP rapid assay test kits. Veterinary software and services for both independent clinics and large corporate veterinary groups are also part of its offerings. The company distributes its extensive product and service catalog through its own dedicated marketing, customer service, sales, and technical service teams, supplemented by independent distributors and other resellers. IDEXX Laboratories, Inc. was established in 1983 and maintains its headquarters in Westbrook, Maine.

Westbrook, ME

11,000 employees

www.idexx.com

Healthcare / Medical - Diagnostics & Research

Sector: Healthcare
Industry: Medical - Diagnostics & Research
CEO: Michael Erickson

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024	Quarter ended Jun 2024
Revenue	4.45B	1.14B	1.09B	1.11B	1.11B	998.43M	954.29M	975.54M	1.00B
Cost of Goods Sold	1.69B	418.08M	432.46M	421.88M	414.73M	375.05M	383.63M	379.50M	382.70M
Gross Profit	2.76B	722.74M	658.11M	683.35M	694.73M	623.38M	570.66M	596.04M	620.88M
Gross Profit Margin	62.1%	63.4%	60.3%	61.8%	62.6%	62.4%	59.8%	61.1%	61.9%
Total Operating Expenses	1.35B	360.15M	342.51M	328.51M	321.69M	306.85M	308.97M	292.15M	355.36M
Research & Development	257.93M	65.79M	66.83M	63.41M	61.90M	59.06M	57.73M	53.98M	55.45M
Selling, General & Administrative	1.09B	294.37M	275.68M	265.09M	259.79M	247.78M	251.25M	238.17M	299.91M
Operating Income (EBIT)	1.41B	362.59M	315.61M	354.85M	373.05M	316.53M	261.69M	303.89M	263.80M
Operating Margin	31.6%	31.8%	28.9%	32.1%	33.6%	31.7%	27.4%	31.2%	26.3%
Income Before Tax (EBT)	1.37B	355.44M	306.98M	344.77M	362.35M	310.08M	256.39M	298.91M	259.06M
Interest Income	2.39M	597K	587K	580K	627K	1.22M	2.20M	2.71M	3.35M
Interest Expense	40.23M	7.74M	10.52M	10.65M	11.32M	7.67M	7.50M	7.70M	8.10M
Other Income/Expense	-36.54M	-7.14M	-8.62M	-10.07M	-10.69M	-6.45M	-5.30M	-4.98M	-4.75M
Net Income	1.10B	278.45M	248.19M	274.61M	293.99M	242.68M	216.15M	232.84M	203.30M
Income Tax Expense	274.31M	77.00M	58.79M	70.16M	68.36M	67.41M	40.24M	66.07M	55.76M
Net Profit Margin	24.6%	24.4%	22.8%	24.8%	26.5%	24.3%	22.7%	23.9%	20.3%
EBITDA	1.55B	400.27M	354.33M	391.47M	408.82M	350.60M	295.39M	338.02M	295.99M
EBITDA Margin	35.0%	35.1%	32.5%	35.4%	36.8%	35.1%	31.0%	34.6%	29.5%
Depreciation & Amortization	148.80M	37.68M	38.72M	36.63M	35.77M	34.06M	33.71M	34.13M	32.19M
EPS Basic	13.67	3.48	3.10	3.43	3.66	2.98	2.63	2.83	2.46
EPS Diluted	13.56	3.45	3.08	3.40	3.63	2.96	2.62	2.80	2.44
Shares Outstanding	80.10M	80.10M	80.10M	80.10M	80.41M	81.32M	81.85M	82.30M	82.63M
Diluted Shares Outstanding	80.67M	80.67M	80.67M	80.67M	80.99M	81.92M	82.54M	83.06M	83.39M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	4.30B	3.90B	3.66B	3.37B	3.22B	2.71B	2.41B	2.21B
Cost of Goods Sold	1.64B	1.52B	1.47B	1.36B	1.33B	1.14B	1.04B	971.70M
Gross Profit	2.66B	2.38B	2.19B	2.00B	1.89B	1.57B	1.37B	1.24B
Gross Profit Margin	61.8%	61.0%	59.8%	59.5%	58.8%	58.0%	56.7%	56.1%
Total Operating Expenses	1.30B	1.25B	1.09B	1.11B	957.40M	876.52M	812.70M	750.21M
Research & Development	251.21M	219.79M	190.95M	254.82M	161.01M	141.25M	133.19M	117.86M
Selling, General & Administrative	1.05B	1.03B	901.89M	850.75M	796.39M	735.27M	679.51M	632.34M
Operating Income (EBIT)	1.36B	1.13B	1.10B	898.76M	932.03M	694.52M	552.85M	491.33M
Operating Margin	31.6%	29.0%	30.0%	26.7%	29.0%	25.7%	23.0%	22.2%
Income Before Tax (EBT)	1.32B	1.11B	1.06B	859.97M	902.65M	661.99M	522.22M	457.74M
Interest Income	2.42M	12.70M	5.63M	1.06M	434K	586K	427K	1.15M
Interest Expense	38.27M	31.20M	41.58M	39.86M	29.81M	33.13M	31.05M	34.74M
Other Income/Expense	-35.84M	-18.51M	-35.95M	-38.79M	-29.37M	-32.54M	-30.63M	-33.59M
Net Income	1.06B	887.87M	845.04M	679.09M	744.85M	581.78M	427.72M	377.03M
Income Tax Expense	264.73M	221.96M	216.13M	180.88M	157.81M	79.85M	94.43M	80.69M
Net Profit Margin	24.6%	22.8%	23.1%	20.2%	23.2%	21.5%	17.8%	17.0%
EBITDA	1.47B	1.26B	1.21B	1.01B	1.04B	790.52M	640.86M	574.51M
EBITDA Margin	34.1%	32.3%	33.1%	30.0%	32.2%	29.2%	26.6%	26.0%
Depreciation & Amortization	106.46M	129.94M	114.91M	111.90M	104.60M	96.00M	88.01M	83.18M
EPS Basic	13.17	10.77	10.17	8.12	8.74	6.82	4.97	4.34
EPS Diluted	13.08	10.67	10.06	8.03	8.60	6.71	4.89	4.26
Shares Outstanding	80.10M	82.47M	83.07M	83.62M	85.20M	85.34M	86.11M	86.86M
Diluted Shares Outstanding	80.67M	83.25M	83.98M	84.60M	86.57M	86.72M	87.54M	88.47M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.